James Topper N.'s Insider Trades & SAST Disclosures
James Topper N.'s most recent trade in Phathom Pharmaceuticals Inc was a trade of 6,300 Common Stock done at an average price of $3.3 . Disclosure was reported to the exchange on May 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern James Topper N..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals Inc | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 3.32 per share. | 13 May 2025 | 6,300 | 55,623 (0%) | 0% | 3.3 | 20,919 | Common Stock |
| Phathom Pharmaceuticals Inc | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 3.16 per share. | 13 May 2025 | 1,120 | 49,323 (0%) | 0% | 3.2 | 3,543 | Common Stock |
| Phathom Pharmaceuticals Inc | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 3.19 per share. | 09 May 2025 | 33,376 | 33,376 (0%) | 0% | 3.2 | 106,563 | Common Stock |
| Phathom Pharmaceuticals Inc | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 3.04 per share. | 09 May 2025 | 12,601 | 48,203 (0%) | 0% | 3.0 | 38,301 | Common Stock |
| Phathom Pharmaceuticals Inc | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 3.62 per share. | 09 May 2025 | 2,226 | 35,602 (0%) | 0% | 3.6 | 8,053 | Common Stock |
| NewAmsterdam Pharma Compan... | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 22.49 per share. | 26 Mar 2025 | 1,135 | 3,013,569 | - | 22.5 | 25,521 | Ordinary Shares |
| NewAmsterdam Pharma Compan... | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 21.02 per share. | 04 Mar 2025 | 4,005 | 3,012,434 | - | 21.0 | 84,203 | Ordinary Shares |
| Phathom Pharmaceuticals Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 10,500 | 32,096 (0%) | 0% | 0 | Common Stock | |
| Alpine Immune Sciences Inc | James N. Topper | Director | 18 May 2024 | 2,829,347 | 0 (0%) | 15% | - | Common Stock | ||
| Alpine Immune Sciences Inc | James N. Topper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 17,500 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | James N. Topper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 10,000 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | James N. Topper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 10,000 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | James N. Topper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | James N. Topper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | James N. Topper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | James N. Topper | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | James N. Topper | Director | 25 Apr 2024 | 1,200,000 | 2,829,366 (15%) | 6% | 0.0 | 1,200 | Common Stock | |
| Alpine Immune Sciences Inc | James N. Topper | Director | 25 Apr 2024 | 1,200,000 | 0 | - | - | Warrant (Right to Buy) | ||
| Alpine Immune Sciences Inc | James N. Topper | Director | Sale of securities on an exchange or to another person at price $ 64.58 per share. | 25 Apr 2024 | 19 | 2,829,347 (15%) | 0% | 64.6 | 1,227 | Common Stock |
| NewAmsterdam Pharma Compan... | James N. Topper | Director | Purchase of securities on an exchange or from another person at price $ 21.50 per share. | 26 Mar 2024 | 8,429 | 3,008,429 | - | 21.5 | 181,224 | Ordinary Shares |
| Alpine Immune Sciences Inc | James Topper N. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 17,500 | 17,500 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | James N. Topper | Director | 11 Dec 2023 | 145,251 | 1,629,366 (8%) | 0% | 12.7 | 1,850,498 | Common Stock | |
| Alpine Immune Sciences Inc | N. Topper James | Director | 11 Dec 2023 | 145,251 | 0 | - | - | Warrant (Right to Buy) | ||
| Phathom Pharmaceuticals Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 9,000 | 21,596 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 3,900 | 3,900 | - | - | Restricted Stock Unit | |
| Alpine Immune Sciences Inc | James N. Topper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to buy) | |
| Phathom Pharmaceuticals Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy | |
| AnaptysBio Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| Alpine Immune Sciences Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to buy) | |
| AnaptysBio Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Alpine Immune Sciences Inc | James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 7,650 | 7,650 | - | - | Stock Option (Right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges